NEW YORK (GenomeWeb News) – After reporting earlier this week that its first quarter revenues declined due to fewer OVA1 tests being performed, Vermillion officials said the firm has recently expanded its sales force and expects to see an uptick in sales of its flagship test beginning in the third quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.